Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;60(8):1385-1389.
doi: 10.1007/s00125-017-4301-8. Epub 2017 May 12.

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

Gian Paolo Fadini  1 , Benedetta Maria Bonora  2 , Angelo Avogaro  2
Affiliations

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

Gian Paolo Fadini et al. Diabetologia. 2017 Aug.

Abstract

Aims/hypothesis: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are indicated for the treatment of type 2 diabetes and may also improve glucose control in type 1 diabetes. In 2015, regulatory agencies warned that SGLT2i may favour diabetic ketoacidosis (DKA). We provide a detailed analysis of DKA reports in which an SGLT2i was listed among suspect or concomitant drugs in the US Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods: We first analysed the entire public FAERS up to September (third quarter [Q3]) 2016 to extract the number of reports, background indications and concomitant medications, and to calculate proportional reporting ratios (PRRs) and safety signals. We then mined single FAERS files from the first quarter (Q1) of 2014 to 2016 Q3 to obtain detailed information on DKA reports.

Results: The FAERS database contains >2500 DKA reports in which SGLT2i are listed as suspect or concomitant drugs. The PRR of DKA in reports including vs those not including an SGLT2i and having a diabetes indication was 7.9 (95% CI 7.5, 8.4) and was higher for type 1 diabetes. Several concomitant conditions were less prevalent in DKA reports with SGLT2i vs DKA reports filed for other drugs. A detailed analysis of 2397 DKA reports for SGLT2i from 2014 Q1 to 2016 Q3 revealed a predominance of women, an extremely wide range of age and body weight, and a highly variable duration of SGLT2i treatment before onset of DKA. In 37 individuals (1.54%), DKA was fatal.

Conclusions/interpretation: Based on the profile of these reports, SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation and can occur at any duration of SGLT2i use.

Data availability: A list of FDA reports analysed in the study is available in the figshare repository, 10.6084/m9.figshare.4903211 . Other data are available from the corresponding author on reasonable request.

Keywords: Case report; Glucose-lowering medications; Pharmacovigilance; Therapy.

PubMed Disclaimer

Comment in

References

    1. Diabetes. 2016 May;65(5):1190-5 - PubMed
    1. Clin Pharmacol Ther. 2007 Aug;82(2):157-66 - PubMed
    1. Drug Saf. 2014 Nov;37(11):971-80 - PubMed
    1. Nat Biotechnol. 2016 Jul 12;34(7):697-700 - PubMed
    1. J Diabetes Complications. 2017 Feb;31(2):468-472 - PubMed

MeSH terms

LinkOut - more resources